Ximelagatran
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Ximelagatran
| |
| Systematic (IUPAC) name | |
| ethyl 2-[[(1R)-1-cyclohexyl-2- [(2S)-2-[[4-(N'-hydroxycarbamimidoyl) phenyl]methylcarbamoyl]azetidin-1-yl]- 2-oxo-ethyl]amino]acetate | |
| Identifiers | |
| CAS number | |
| ATC code | B01 |
| PubChem | |
| Chemical data | |
| Formula | C24H35N5O5 |
| Mol. mass | 474 (429 after conversion) |
| Pharmacokinetic data | |
| Bioavailability | 20% |
| Metabolism | None |
| Half life | 3-5h |
| Excretion | Renal (80%) |
| Therapeutic considerations | |
| Pregnancy cat. |
uncategorised |
| Legal status |
Rx only/POM |
| Routes | Oral |
|
WikiDoc Resources for Ximelagatran | |
|
Articles | |
|---|---|
|
Most recent articles on Ximelagatran Most cited articles on Ximelagatran | |
|
Media | |
|
Powerpoint slides on Ximelagatran | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Ximelagatran at Clinical Trials.gov Clinical Trials on Ximelagatran at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Ximelagatran
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Ximelagatran Discussion groups on Ximelagatran Patient Handouts on Ximelagatran Directions to Hospitals Treating Ximelagatran Risk calculators and risk factors for Ximelagatran
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Ximelagatran | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Ximelagatran (Exanta® or Exarta®, H 376/95) is an anticoagulant that has been investigated extensively as a replacement for warfarin that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy. In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries where the drug had been approved.
Method of action
Ximelagatran was the first member of the drug class of direct thrombin inhibitors that can be taken orally. It acts solely by inhibiting the actions of thrombin. It is taken orally twice daily, and rapidly absorbed by the small intestine. Ximelagatran is a prodrug, being converted in vivo to the active agent melagatran. This conversion takes place in the liver and many other tissues through dealkylation and dehydroxylation (replacing the ethyl and hydroxyl groups with hydrogen).
Uses
Ximelagatran was expected to replace warfarin and sometimes aspirin and heparin in many therapeutic settings, including deep venous thrombosis, prevention of secondary venous thromboembolism and complications of atrial fibrillation such as stroke. The efficacy of ximelagatran for these indications had been well-documented (Eriksson et al 2003, Frances et al 2004, Schulman et al 2004).
An advantage, according to early reports by its manufacturer, was that it could be taken orally without any monitoring of its anticoagulant properties. This would have set it apart from warfarin and heparin, which require monitoring of the international normalized ratio (INR) and the partial thromboplastin time (PTT), respectively. A disadvantage recognised early was the absence of an antidote in case acute bleeding develops, while warfarin can be antagonised by vitamin K and heparin by protamine sulfate.
Side-effects
Ximelagatran was generally well tolerated in the trial populations, but a small proportion (5-6%) developed elevated liver enzyme levels, which prompted the FDA to reject an initial application for approval in 2004. The further development was discontinued in 2006 after it turned out hepatic damage could develop in the period subsequent to withdrawal of the drug. According to AstraZeneca, a chemically different but pharmacologically similar substance, AZD0837, is undergoing testing for similar indications (AstraZeneca press release 2006).
References
- AstraZeneca (February 14, 2006). AstraZeneca Decides to Withdraw Exanta. Press release.
- Eriksson, H; Wahlander K, Gustafsson D, Welin LT, Frison L, Schulman S, THRIVE Investigators (January 2003). "A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I". Journal of Thrombosis and Haemostasis 1: 41–47. PMID 12871538.
- Francis, CW; Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW Jr; EXULT A Study Group (October 2003). "Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement". New England Journal of Medicine 349 (18): 1703–1712. PMID 14585938.
- Schulman, S; Wåhlander K, Lundström T, Clason SB, Eriksson H, THRIVE III investigators (October 2003). "Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran". New England Journal of Medicine 349 (18): 1713–1721. PMID 14585939.
- Weitz, JI (August 2004). "New anticoagulants for treatment of venous thromboembolism". Circulation 110 (Suppl 1): 19–26. PMID 15339877.
WikiDoc Research Resources for Ximelagatran | |
|---|---|
| Articles on Ximelagatran | Most recent articles on Ximelagatran • Most cited articles on Ximelagatran • Review articles on Ximelagatran • Articles on Ximelagatran in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Ximelagatran | Powerpoint slides on Ximelagatran • Images of Ximelagatran • Photos of Ximelagatran • Podcasts & MP3s on Ximelagatran • Videos on Ximelagatran |
| Evidence Based Medicine Regarding Ximelagatran | Cochrane Collaboration on Ximelagatran • Bandolier on Ximelagatran • TRIP on Ximelagatran |
| Cost Effectiveness of Ximelagatran | Cost Effectiveness of Ximelagatran |
| Clinical Trials Involving Ximelagatran | Ongoing Trials on Ximelagatran at Clinical Trials.gov • Trial results on Ximelagatran • Clinical Trials on Ximelagatran at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Ximelagatran | US National Guidelines Clearinghouse on Ximelagatran • NICE Guidance on Ximelagatran • NHS PRODIGY Guidance • FDA on Ximelagatran • CDC on Ximelagatran |
| Textbook Information on Ximelagatran | Books and Textbook Information on Ximelagatran |
| Pharmacology Resources on Ximelagatran | Dosing of Ximelagatran • Drug interactions with Ximelagatran • Side effects of Ximelagatran • Allergic reactions to Ximelagatran • Overdose information on Ximelagatran • Carcinogenicity information on Ximelagatran • Ximelagatran in pregnancy • Pharmacokinetics of Ximelagatran • |
| Genetics, Pharmacogenomics, and Proteinomics of Ximelagatran | Genetics of Ximelagatran • Pharmacogenomics of Ximelagatran • Proteomics of Ximelagatran |
| Newstories on Ximelagatran | Ximelagatran in the news • Be alerted to news on Ximelagatran • News trends on Ximelagatran |
| Commentary on Ximelagatran | Blogs on Ximelagatran |
| Patient Resources on Ximelagatran | Patient resources on Ximelagatran • Discussion groups on Ximelagatran • Patient Handouts on Ximelagatran • Directions to Hospitals Treating Ximelagatran • Risk calculators and risk factors for Ximelagatran |
| Healthcare Provider Resources on Ximelagatran | Symptoms of Ximelagatran • Causes & Risk Factors for Ximelagatran • Diagnostic studies for Ximelagatran • Treatment of Ximelagatran |
| Continuing Medical Education (CME) Programs on Ximelagatran | CME Programs on Ximelagatran |
| International Resources on Ximelagatran | Ximelagatran en Espanol • Ximelagatran en Francais |
| Business Resources on Ximelagatran | Ximelagatran in the Marketplace • Patents on Ximelagatran |
| Informatics Resources on Ximelagatran | List of terms related to Ximelagatran |
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
